Voxilaprevir
- Generic Name
- Voxilaprevir
- Brand Names
- Vosevi
- Drug Type
- Small Molecule
- Chemical Formula
- C40H52F4N6O9S
- CAS Number
- 1535212-07-7
- Unique Ingredient Identifier
- 0570F37359
- Background
Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affectin...
- Indication
Vosevi (Voxilaprevir/Sofosbuvir/Velpatasvir) is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection who have previously been treated with an HCV regimen containing Sofosbuvir without an NS5A inhibitor .
- Associated Conditions
- Previously treated with an HCV regimen containing an NS5A inhibitor Chronic Hepatitis C Genotype 1, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 2, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 3, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 4, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 5, Previously treated with an HCV regimen containing an NS5A inhibitor Chronic hepatitis C genotype 6, Previously treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor Chronic hepatitis C genotype 1a, Previously treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor Chronic hepatitis C genotype 3
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.